The Meaning of Myriad

Friday, September 12, 2014
9:00 a.m.–5:00 p.m.
University of California, Irvine

In 2013, the United States Supreme Court rendered its decision on gene patenting in Association of Molecular Pathology v. Myriad Genetics, ending 30 years of United States Patent Office patent practice and seemingly placing the United States out of step with the patent policy of many of its trading partners. A year later, the reasoning of the Myriad decision itself remains anything but clear, as does its potential effect on the patent eligibility of other technologies and on the patent policy of other jurisdictions. This conference will explore the evolving meaning of the Myriad decision for science, for industry, and for the patent system.

Keynote Speaker

Hon. Andrew Guilford, USDC Cent. Dist. Cal

Confirmed Speakers